-
- The most powerful and most effective anti-cancer agents ever developed are known as cytotoxic drugs, meaning that they kill cancer cells by inflicting lethal damage. Cytotoxic chemotherapy has been the mainstay of cancer therapy for the past 40 years and is set to continue to hold that position for the foreseeable future.
But cytotoxic chemotherapy has hit a roadblock. It has not advanced in any meaningful way in the last 20 years for two fundamental reasons:
first, it has no effect on cancer stem cells, those minority cells within a tumor that are responsible for perpetuating the tumor. So that even where initial response to therapy has occurred, malignant cancer almost always returns;
second, most forms of cancer either have from the start or quickly develop drug-resistance mechanisms that render them insensitive to cytotoxic drugs.
Novogen has focused on breaking through this roadblock. Our objective has been to find ways both to kill the cancer stem cells, as well as augmenting the cytotoxic effect of standard drugs in their ability to kill the regular cancer cells.
In this quest, Novogen scientists have identified two new drug targets.
The second target is a structural protein that when disabled, causes the cancer cell’s cytoskeleton to disintegrate. We have developed a drug that by hitting this target greatly potentiates the anti-cancer effect of some of the most widely used drugs in oncology. This is the anti-tropomyosin drug
One target is a family of secondary or enabling mutations that we believe are common to all cancer cells and which are essential for a cancer cell’s survival. We have developed a family of drugs that hit this target and for the first time kill the full range of cells within a tumor, but most importantly the cancer stem cells. This is the super-benzopyran drug technology.
- HISTORY
-
-
I second that JT
A great company & from what I can make out a trail blazer in cancer treatment !!!
-
Have a friend who's long/heavily in NRT, totally guessing but I would think this is pretty substantial. Discl, not holding and neither of us know the first thing about biotechnology/oncology etc
http://www.novogen.com/pdf/150605_TR...rosses_BBB.pdf
-
SNNLive - Novogen Limited (NASDAQ: NVGN) - YouTube
Heres a very simple clear intro into what and where NRT are at.
-
Member
Prima Biomed (PRR) seems to perform well on good news. A few weeks ago it skyrocketed +750% before sliding back South and it went up +44% today. Not sure if their product will lead to a commercial success but, on the shorter term, surely some more good news could build a speculative hype and send the SP higher like it did with PEB. Worth watching!
-
Finally bought a few PNV @ 9.5c. Two new announcements this month have helped the s/p atp.
Download Document
Download Document
-
 Originally Posted by Joshuatree
Yes JT, it can be a long wait between news with these biotech's - always a lot of promises/high hopes followed by multiple delays. Often the managers who are usually a bunch of enthusiastic scientists dont quite have the experience or skill to run publicly listed companies, however they have good intentions.
Glad to see some good stuff come from PNV, it seems they have a real product with real potential. There was a presentation a year or so ago that had a bunch of somewhat gory pictures of if i remember correctly burns treated with their product pre-skin-graft which In my opinion showed clinically impressive results.
Makes this a take-over in my opinion by a big competitor so they could take the technology.
Last edited by NZSilver; 10-07-2015 at 10:15 AM.
Reason: spelling
-
https://www.sec.gov/Archives/edgar/d.../d28048d6k.htm
May give NRT s/p a lift today.
Decided to take a quick profit on PNV with mkt issues so out @ 11c.
-
Member
Another good news on the NRT front: “Anisina receives orphan drug designation from FDA”.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Reply With Quote
Bookmarks